September 21, 2017
Article
Adjuvant therapy with TKIs for patients with high-risk renal cell carcinoma who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines, yet this approach is still controversial, with many physicians believing that there are not yet enough data in support of its use.
September 19, 2017
Article
Lori J. Wirth, MD, discusses the era of precision genotype targeted therapy in advanced thyroid cancer, with a focus on individual targets in subtypes of thyroid cancer.
September 16, 2017
Article
Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.
August 18, 2017
Article
There is a great deal of excitement in the oncology field over the use of peptide receptor radionuclide therapy with lutetium-177 (177Lu)-octreotate (177 Lu-Dotatate, Lutathera) for the treatment of patients with neuroendocrine tumors. The treatment is being explored in potential combinations with other modalities, including with systemic treatment with PARP inhibitors, in this patient population.